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Rceommendatioas 
1. Athletes with myocardial bridging of an epicardial cor- 
onary artery and no evidence of myocardia! ixhemia at rest or 
during exercise can participate in ail competitive sports. 
2. Athletes with myocardial bridging of an epicardial coronary 
artery and objective vidence of myocardial ischemia should be 
restricted to low intensity competitive sports (claxs IA). 
Recommendations for other coronary artery anomalies, 
including anomalous origin of the left main coronary artery, 
are included in Task Force 1. 
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General Considerations 
Guidelines for athletic participation are needed to reduce 
the risk for arrhythmia-related morbidity or mortality. How- 
ever, it is often difficult o establish the importance ofa cardiac 
rhythm disturbance in assessing an athlete’s eligibility for 
competition. Few data exist hat have been obtained prospec- 
tively from well designed, scientifically acceptable studies to 
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determine whether a ~articuIar ~l~ytbm islurbance predisposes 
to symptoms, such as syncope or 
itate severe injury. Sudden unex- 
is rare (12). It bas been 
< 1% of that in adults (3). 
ion of these deaths occur in 
relation to exercise. s of Reggie Lewis and Hank 
Gathers have focused attention on athletes with known arrhyth- 
mias (4). 
ArrhyFhmias commonly arc cvancsccnt, often disappearing 
unpredictably forlong periods of time, in some cases years. If they 
recur when the athlete is not exercising, the arrhythmia may not 
be noted or may not produce significant symptoms. The same 
i~r~l~ythmia may mini ally affect acompetitive golfer but severely 
incapacitate other athletes, uch as c~oss~c{~uut~~ skiers perform- 
ing at peak physical ebrt. The athlete may not develop the 
arrhythmia during each sporting cvcnt. Ahbougb tbc reasons for 
this are not known, factors rcIatcd to the autonomic nervous 
system probably play a vcty important role in dcFcrmining 
whether an arrhythmia occurs and its rate and clfect on 
namic responses and sy~~pto~l~s (5). AuF~)~~~ulic “‘tone” 
varies greatly and perhaps unpredictably between an 
athletic events and from one athlete to another. Mental stress 
during competition can produce imporrant electrophysiologic and
hemodynamic changes that are probably mediated through the 
autonomic nervous ystem. 
It is important to understand the range o 
and rhythm for the trained athlete (6,‘;): 
beats/min and sinus pauses lasting >2 s may be found on 24-h 
Holter ambulatory electrocardiographic (ECG) recordings. 
Type I second-degree atrioventricular (AV) block and single 
uniform premature ventricular complexes each may occur in 
-40% of athletes. Complex ventricular arrhythmias (multi- 
form premature ventricular complexes, couplets, nonsustained 
ventricular tachycardia) re rare (7). 
Many of our conclusions result from data obtained in nonath- 
letes, from general perceptions or experience and from a heavy 
input of “what seems reasonable.” Decision making based on this 
type of logic is often fauhy but is the best available. Recommen- 
dations and guidance need to be balanced between an effort to 
avoid restricting activity unduly and the hope of reducing the risk 
of death and injury due to a rhythm disturbance. 
Despite the lack of certain information, some firm conclusions 
can be reached. Certain arrhythmias create symptoms and are 
dangerous in and of themselves regardless of the clinical situation 
in which they occur (8). These arrhythmias generally are charac- 
terized by very rapid or very slow heart rates that significantly 
compromise cardiac output, coronary or cerebral blood flow or 
maintenance of blood pressure. Such arrhythmias may include 
atrial flutter or fibrillation with uncontrolled ventricular rates of 
200 to 300 beatslmin, usually (but not exclusively) in athletes with 
Wolff-Parkinson-White syndrome, rapid sustained ventricular 
tachycardias and AV block or sinus node disease with very slow 
ventricular rates. Certain persistent arrhythmias, such as chronic 
supraventricular t chycardia, can worsen cardiac function (9). 
Other arrhythmias, uch as AV node reentrant achycardia, 
generally well tolerated in most people, may noF produce impor. 
taut symptoms atrest but only during exercise in athletes with 
structural heart disease due, in part, to an increase in the 
ias that might otherwise be innocuous 
nuisance might, under conditions of partici- 
rts involving body contact or high speed, 
place the athlete at risk of injury or death because of transient 
impaired mental function causing loss of physical control, Par 
example, an athlete with supraventricular tachycardia p rticipat- 
ing in potentially dangerous sports, uch as diving, downhill skiing 
or auto racing, may be at greater risk because of dizziness, near 
syncope (afeeling of impending loss of consciousness) or syncopc 
than if he or she were playing basketball orbaseball 
Some athletes with coronary heart disease (IO), hypertro- 
phic cardiomyopathy (I I,l2), arrhythmogenic r ght ventricular 
lasia (13) aortic stenosis (14) and other forms of congen- 
ital bearl disease (1) are probably at greater isk for cardiac 
sudden death during and just after exercise. This is 
probably true whether or not arrhythmias have been recog- 
nized previously (15-17). In general, atltlctcs with symptoms 
possibiy rclated to cardiac arrhythmia, such as syncope, near 
syncopc and palpitations, hould be carefully evaluated before 
being permitted to participate in competitive sports. A consid- 
eration of cardiac hemodynamic status is critical because right 
or left ventricular dysfunction is an additional important 
predictor of arrhythmic death (18,19). The presence of a 
significant rhythm disturbance in athletes with abnormal car- 
diac hemodynamic status (from any cause unrelated to the 
arrhythmia), itself is definitely incompatible with participation 
in all competitive sports. However, it is important to emphasize 
that some disease states that produce arrhythmias can be 
self-limited, with subsequent full recovery. 
In general, all athletes with significant cardiac arrhythmias 
being considered for athletic activity should have a l2-lead ECG, 
echocardiogram, exercise test and a long-term 24-h Holter am- 
bulatory ECG recording, if possible during the specific type of 
exercise being considered. Resuscitation equipment and trained 
personnel may be needed on a standby basis for the latter test, 
which is deemed important because a conventional exercise test 
may not replicate the specific linical situation produced by 
actively participating in the sport. In this regard, exercise t sts 
may need to be adapted specifically for the athlete; that is, to 
begin exercise at peak energy expenditure, asa sprinter in a race 
might, rather than with the slow increase inwork load commonly 
used in testing athletes with coronary artery disease. 
All athletes with an arrhythmia who are permitted to 
engage in athletics should be reevaluated atintervals after they 
are “trained,” to determine whether the conditioning process 
affected the arrhythmia. It should also be stressed that athletes 
with arrhythmias controlled by antiarrhythmic drugs may stop 
Faking these drugs for a variety of reasons, and therefore 
comnhance with recommended therapy must be established 
periodically. Coaches and team physicians must continually 
question players about palpitations, with or without physical 
activity. Abuse with drugs like cocaine can be responsible for 
life-threatening arrhythmias, and such considerations are au 
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important part of the evaluation. Of note, the use of certain 
cardioa&e drugs, such as beta-adrenergic blocking agents, is 
banned in some competitive sports. 
It may be difficult for a team physician and consultants from 
the locaJ community to make objective decisions to restrict or 
proscn’be sports for a competitive athlete. It has been sug- 
gested (4) that borderline cases be reviewed by nonbiased 
experts for the purpose of making these decisions more 
efIicientiy. Whether that approach can be practically imple- 
mented has not been determined. Alternatively, it has also 
ted that in such borderline cases, both appropriate 
uipment and medical professionals versed in the 
that equipment bc present at all practices and 
er, there is considerable concern with regard to 
practice because its safety and eflicucy have not been 
established. Indeed, the practical implementation and rcliabil- 
ity of this approach to rcvenc potentially lethal arrhythmias in 
nonhospital settings is highly questionable. 
Unexplained syncope te is a potentially impor- 
tant symptom that requires a thorough evaluation. It may be 
due to a variety of causes, including cardiovascular disease; 
alternatively, it may be unassociated with structural heart 
disease but due to mechanisms uch as vasovagal syncope, a 
not uncommon finding in highly trained athletes. Although 
vasovagal syncope is compatible with continued participation 
in all competitive sports, caution should be used in making this 
rained athletes without first defi,,itively 
structural cardiovascular disease. A car- 
Id be considered, particularly when syn- 
cope occurs during or immediately after exercise. 
A cause of syncope can be established in -50% of patients. 
Ustudly, a careful history and physical examination will identify 
the eti When such an evaluation does not determine 
the ca r testing in search of an arrhythmia is indi- 
Wed. Ambulatory BCG recordings are often unrevealing but 
nwwthdes probably worthwhile to obtain during the initial 
evaluation. Event or loop recorders can be used to increase the 
ECG sampling time. Tilt table testing has been used to assess 
but the lack of specikity of 
ruined athletes) requires a 
the results. Exercise testing 
is rrSeful and is optimally performed while recording the ECG 
during the sport activity in which the athlete participates. Invasive 
~lectrophysiQlogic testing is most likely to identify an arrhythmia 
ns& for ape in those patients with cardiac disease or 
an abnormal ECG but should be considered in other athletes 
when no other cux of the synczope has been identified. 
Disturbances of Sinus Node Function 
Sinus tachycardia nd sinus bradycardia appropriate for the 
clinical situation are not considered abnormal, and no rests are 
necessary. Sinus arrhythmia and wandering pacemaker are 
generally considered normal, and no tests are necessary unless 
the arrhythmias result in inappropriately slow rates accompa- 
nied by symptoms. Sinus arrhythmia and sinus bradycardia are 
particularly common in the trained athlete. 
Asymptomatic sinus pause or sinus arrest C3 s is probably 
of no significance (7). Longer pauses, sinoatrial exit block and 
sick sinus syndrome (21) are considered abnormal, and ath- 
letes should have a 12-lead and 24-h ECG and an exercise test. 
In an occasional athlete experiencing syncope or near syncope, 
an electrophysiologic study may be indicated. 
phy should be performed to exclude structu 
and other tests to ev~l~~tc ventric 
be indicated. 
Athletes with a normal or structl~r~~lly i~bnorm~~ heart in 
whom the bradycardic rate is increased appr~priatc~y by 
physical activity can p~rtici~tc in all compctitivc sports. They 
should be reassessed per Ily to determine that training 
does not aggravate the br 
2. &hletes with synco near syncopc should not par- 
ticipate in sports where the likelihood of even a momentary 
loss of consciousness may be hazardous until the cause has 
been determined and treated, if necessary. 
3. Athletes witb symptoms uch as impaired c~~~~ous~e~s 
and fatigue clearly attributed to the arrhythmias Id be 
treated and if asymptomatic for 3 to 6 months du treat- 
ment, can participate in all competitive sports after physician 
reevaluation. 
4. Athletes with ~tomatic t~c~ys~rdi~radyc~rdia syn- 
drome or inappropriate sinus tachycardia should be treated. If 
asymptomatic for 3 to 6 months, they can participate in low 
intensity competitive sports (class IA [see Table 1 in Classification 
of SportsJ). 
5. Athletes with pacemakers hould not engage in sports 
with a danger of bodily collision becltuse such trauma may 
damage the pacemaker system. 
Premalune Atria1 Complexes 
In the absence of evidence obtained from a careful history or 
physical examination suggesting the presence of structural heart 
disease, and in the absence of symptoms other than occasional 
palpitation, evaluation other than a lblead ECG is not necessary. 
Recommendation. Athletes can participate in all competi- 
tive sports. 
Atria1 Flutter (in the Absewe of 
Wolff-Parkinson- Mite Syndrome) 
In the absence of an acute, limiting illness, sustained atria1 
flutter is an uncommon rhythm disturbance in athletes without 
structural heart disease. Therefore, an echocardiogram should 
be performed to evaluate cardiovascular structure and func- 
tion. Because the potential for very rapid ventricular rates 
exists if the atrial flutter conducts 1:I to the ventricles (22), 
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EC ination of the ventricular esponse d~~~~g an 
exercise test or athl 
atients with 
mia by electrncal stimu tion may be necessary before 
the exercise test. A 12-lead an ~o~g~ter~~ 24-h ECG are also 
necessary. 
eeo 6 
1. .4thletes with atria! utter in the absence ofstructural heart 
disease who maintain aventricular rate comparable tot 
appropriate sinus tacbycardia during physical ctivity whi 
italis glycoside, a beta-blocker o calcium 
~artic~~atc in low intensity competitiv 
id I:1 c(~~~d~cti~a sti 
may occur. However, full partici~t~ot~ in all competitive sports 
rould not be aliowsd unless tile athlete has been without atrial 
utter for 3 lo 6 months with or with~~~lt trc~ltl~le~it. 
es with structural heart diSeilSl! who have atrial 
arlicipate in low intc:aity co~~~petitivc sports only 
(class lA) after (-I ~~~~nt~~s have elapsed with 
atrial flutter. 
Atria1 ~ibrii~~~i~~~ (in the Absence 
?f ire S~atdrome) 
Atrial fil~ril~ation s far more common than atrial flutter and 
may be present intermittently or chronically (23). Evaluation 
should include a search for the cause, such as thyrotoxicosis. 
More often atrial fibrillation occurs in association with diseases 
such as coronary artery disease or hypertension. Evaluation 
includes determination of the ventricular esponse during 
athletic activity or an exercise test comparable to the intended 
athletic ompetition. For some patients with paroxysmal trial 
fibrillation, electrical induction of atrial fibrillation before the 
exercise test may be necessary. A 12-lead ECG is necessary, 
and long-term 24-h ECG recordings and an echocardiogram 
are helpful in establishing the presence of structural heart 
disease. 
Recommendations 
1. Athletes with atrial fibrillation in the absence of struc- 
tural heart disease who maintain aventricular rate comparable 
to that of an appropriate sinus tachycardia during physical 
activity while receiving no therapy or therapy with a digitalis 
glycoside, a beta-blocker or calcium channel blocker can 
participate in all competitive sports. Note that the use of 
beta-blockers is prohibited in some competitive sports. 
2. Athletes who have atrial fibrihation in the presence of 
structural heart disease who maintain a ventricular rate com- 
parable to that of an appropriate sinus tachycardia during 
physical activity while receiving no therapy or therapy with a 
digitalis glycoside, a beta-blocker or calcium channel blocker 
can participate in sports consistent with the limitations of the 
structural heart disease. 
3. Athletes who require anticoagulation should not partic- 
ipate in sports with danger of bodily collision. 
ardia, including auto- 
a due to reentry, atria! 
evaluated as described for atrial flutter (23). 
nus node reentry or atrial tachycardia n
ructural heart disease who maintain aventric- 
ular rate comparable tothat of an appropriate sinus tachycar- 
dia during physical activity with or without herapy can partic- 
ipate in all competitive sports. 
2. Athletes with un erlying structural heart disease cam 
ate only in competitive sports consistent with the 
limitations of the heart disease. 
trioventriclllar junctional escape beats and junctional 
rhythm are co~iirno~l in athletes. The clinical approach and 
final recommendations are the same as those given earlier for 
symptomatic athletes with disturbances of sinus node function 
(see earlier). 
mature A V Junctiorlal Comphes 
If the athlete is asymptomatic except for occasional epi- 
sodes of palpitations that do not suggest a sustained tachycar- 
dia, evaluation eed include only a 12-lead ECG. In some 
athletes, a 24-h ECG recording (during athletic activity if 
possible), echocardiogram and an exercise test may be indi- 
cated. 
1. Athletes with a structurally normal heart and a normal 
heart rate response to activity without evidence of a sustained 
tachycardia c n participate in all competitive sports. 
2. Athletes with an abnormal heart, depending on the type 
and extent of the heart disease, cam participate in competitive 
sports consistent with the limitations of the structural cardiac 
disease. 
Nonparoxysmal A V Junctional Tachycardia 
Noninvasive tests required include a 1Zlead ECG, echo- 
cardiogram, exercise test and 24-h ECG recording during 
activity. Invasive studies m&y be necessary for some symptom- 
atic patients or for those with very rapid ventricular rates (24). 
eeommendations 
1. Athletes without structural heart disease or symptoms 
who have a controlled ventricular rate that increases and slows 
appropriately inrelation to the level of activity with or without 
therapy can participate in all sports. 
2. Athletes who have no symptoms but who have structural 
heart disease or incompletely controlled ventricular rates can 
engage in low intensity competitive sports (class IA), depend- 
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ing on the nature and extent of the structural heart disease and 
the ventricular rate. 
Supraventricuhr Tachycardia 
Atrioventricular node reentry tachycardia and AV reentry 
over a concealed accessory pathway (with only retrograde 
conduction) (8) are included in this category. If the diagnosis 
of the supraventricular tachycardia c nnot be made with 
certainty, and if other clinical therapeutic c rcumstances war- 
rant it, invasive electrophysiologic studies may bc indicated. It 
is important toidentify the rate response ofthe suprdventric- 
ular tachjeardia during exercise, If the exercise does not 
induce the tachycardia, attempts toinduce the supraventricular 
tachycardia (possibly with atria1 or esophageal p cing) may be 
usefut, followed once again by an exercise t st performed by 
the athlete when the sslpraventricular tachycardia h s been 
initiated. 
1. Athletes who are asymptomatic nd have reproducible 
exercise-induced supraventricular tachycardia in whom pre- 
vention of recurrences by therapy has been demonstrated by 
appropriate testing can participate in all competitive sports. 
2. Athletes who do not have xercise-induced supraventric- 
ular tachycardia butexperience sporadic recurrences should be 
treated. However, because ofthe unpredictable nature of the 
tachycardia, end points for adequate therapy may be difficult to 
achieve; but once established, these athletes can participate in 
all sports. Asymptomatic athletes who have episodes of su- 
praventricular tachycardia of 5 to IO s that do not increase in
duration during exercise can participate in all sports. 
3. Athletes with syncope, near syncape orsignificant palpi- 
tations secondary to arrhythmia or who have significant struc- 
tural heart disease in addition to the arrhythmia should not 
rticipate in any competitive sports until they have been 
quately treated and have no recurrence for h6 months (4). 
At that time they can participate in low intensity competitive 
sports (class IA). 
4. For those athletes with successful catheter or surgical 
ablation (2%26) who are asymptomatic nd have no inducible 
arrhythmia on follow-up electrophysiologic testing (or no 
recurrence of tachycardia for3 to 6 months after ablation), all 
competitive sports are permitted. 
Venhicular Pm-Ekcitatiora 
f Fankinson- white Syndrome) 
ired noninvasivz tests include a K&lead ECG, a 24-h 
ECG recording during athletic activity, exercise test and 
ec iogram to exclude associated cardiovascular abnor- 
malit& Electrophysiologic studies may be indicated insome 
athletes with palpitations who appear at risk for developing 
tachycardias, such as those with symptoms of impaired con- 
sciousness, long-lasting palpitations or rapid rates (27). 
In asymptomatic thletes with no history of palpitations or 
tachycardia and no evidence of structural cardiac abnormali- 
ties, further evaluation is probably not necessary. However, the 
optimal management for these athletes is uncertain, and 
continues to be debated (6,28,29). Sudden death in athletes 
with pre-excitation is rare (28,29), and it appears to be 
confined largely to those with accessory pathways that have 
short refractory periods. Therefore, it may be advisable in
selected athletes to undertake esophageal pacing or intracar- 
diac electrophysiologic studies to identify the presence ofan 
accessory pathway that has a short refractory period. Atrial 
fibrillation should be induced and the shortest 
assessed. If a short refractory period is found, radi 
catheter ablation may be considered. However, in those ath- 
letes with a history of palpitations, syncope ornear syncope, it 
is mandatory to assess the functional capabilities and electro- 
physiologic properties of the accessory pathway (30). 
1. Athletes without structural heart disease, a history of 
palpitations or tachycardia (particularly those >20 years old) 
can participate in all competitive sports. However, inyounger 
age groups, amore in-depth evaluation may be recommended 
before allowing participation i  moderate to high in:ensity 
competitive sports. 
2. Athletes with episodes ofAV reciprocating tachycardia 
should be treated as previously recommended (see Supraven- 
tricular Tachycardia). However, it should be appreciated that 
they call develop atrial fibrillation with rapid ventricular rates. 
Electrical induction of atrial fibrillation to determine the 
shortest QRS interval between two complexes conducted over 
the accessory pathway during isoproterenol administration or 
exercise is recommended. 
3. Athletes with episodes ofatrial flutter/fibrillation whose 
maximal ventricular rate at rest (without therapy) as a result of 
conduction over the accessory pathway is 1240 beatslmin and 
who have no episodes of syncope or near syncope appear to be 
at low risk for sudden cardiac death and can participate in all 
competitive sports (31). However, despite this apparent risk- 
stratifying test, those with very rapid ventricular rates probably 
should be considered for radiofrequency ablation of the ac- 
cessory pathway. Athletes with syncope or near syncope or 
episodes ofatrial flutter/fibrillation whose maximal ventricular 
rate at rest (without therapy) as a result of conduction ver the 
accessory pathway exceeds 240 beatslmin are restricted tolow 
intensity competitive sports (class IA). They should be consid- 
ered for radiofrequency catheter ablation of the accessory 
pathway. 
4. Athletes with successful catheter or surgical ablation of 
the accessory pathway who are asymptomatic nd have normal 
AV conduction and no inducible arrhythmia by follow-up 
electrophysiologic study or no spontaneous recurrence of
tachycardia for3 to 6 months after ablation can participate in 
all competitive sports. In selected athletes, the desired partic- 
ipation in sports can be an indication for catheter ablation of 
the accessory pathway. 
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structural heart di 
24-b ECG recordi 
premature v ntricular complexes or 
rhythmias occurs during exercise, fu
indicated (6,32). hn some of these at have a 
structurally normal heart, cardiac ca~beterizat~on aJ a gmg- 
raphy may reveal otherwise undetected abnormalities, includ- 
ing occult coronary artery disease, congenital coronary anom- 
ogeuic right ventricular dysplasia, cardiac tumor 
I beast disease who have pre- 
mature ventricular complexes at rest, during exercise and 
exercise t sting (comparable to the sport iu wbicb they com- 
pete) can participate in all competitive 
premature v ntricular complexes increase 
exercise or exercise testing to the extent hat they produce 
symptoms of impaired consciousness, significant fatigue or 
dyspnea, the athlete can participate in low intensity competi- 
tive sports only (class IA). 
2. Athletes with structural heart disease who are in high 
risk groups and have premature v ntricular complexes (with or 
without treatment) can participate in low intensity competitive 
sports only (class IA). Athletes with premature ventricular 
complexes that are suppressed by drug therapy (as assessed by 
ambulatory ECG recordings) during participation in the sport 
can compete inlow intensity competitive sports only (class IA). 
Ventticular Tachycardia 
Nonsustained or sustained monomorphic or polymorphic 
ventricular tachycardia is always a potentially serious occur- 
rence. Noninvasive t sts to be performed include a 12-lead 
ECG, exercise t st, 24-h ECG recording during exercise and 
echocardiography. Cardiac atheterization and electrophysi- 
obgic study should be considered to verify that the heart is 
structurally normal and to establish t e mechanism or location, 
or both, of the ventricular tachycardia. 
Recommendations 
1. Athletes with nonsustained or sustained ventricular 
tachycardia on any of the aforementioned tests generally 
should not compete inall sports for at least 6 months after the 
last episode of ventricular tachycardia. This recommendation 
applies whether the athlete isuntreated ortreated with either 
drugs or catheter or surgical blation. Ef there have been no 
clinical recurrences, and ventricular tachycardia is not induc- 
ible by exercise orexercise t sting and electrophysiologic study, 
and the athlete has no structural heart disease, all competitive 
sports may be permitted. For the athlete with structural heart 
disease and ventricular tachycardia, moderate and high inten- 
sity competition is contraindicated r gardless of whether the 
pressed. Only 10~ intens@ corn-- 
ion to this general recomme~ ation is the asymp- 
tomatic Mete with brief (generally <8 to 10 consecutive 
ventricular beats) episodes of nonsustained monomorphic 
ventricular tachycardia, r tes generally <I50 beats/min a d no 
structural heart disease established by noninvasive and invasive 
es do not appear to be at inc 
th. If exercise t sting (prefe 
latory ECG recording during the specific ompetitive sport) 
demonstrates suppression f the ventricular tachycardia or no 
significant worsening compared with baseline, participation in 
all competitive sports is permissible. 
2. Continued atbietic competition should not represent the 
primary indication for au implantable d fibrillator. The e&cacy 
with wKcll these devices will terminate a potentially ethal 
arrhythmia under the extreme conditions of competitive sports 
is currently unknown For athletes with implantable d hbrilla- 
tors or antitachycardia devices, all moderate and high intensity 
orts arc coutraiud~cated. Low intensity competitive sports 
activity (class IA) that does not constitute a significant risk of 
trauma to the defibrillator is also contraindicated for at least 6 
months after the last ventricular rhythmia requiring inter- 
vention (pacing, cardioversion or defibrillation). Subsequently, 
these athletes can participate in low intensity competitive 
sports only (class IA). 
Ventricular Flutter and Ventricuhzr Fibrillation 
. Athletes with these conditions that re- 
sult in cardiac arrest in the presence orabsence ofstructural 
heart disease cannot participate in any moderate or high 
intensity competitive sports. However, athletes who have had 
no episodes ofventricular flutter or ventricular fibrihation for 
6 months with treatment may engage inlow intensity compet- 
itive sports (class IA). Recommendations n the section on 
ventricular tachycardia also apply. 
First-Degree A V Block 
If the QRS complex isnormal, no further evaluation ther 
than a 12-lead ECG is necessary. If the QRS complex ir
abnormal, or the PR interval isexcessively prolonged (20.3 s), 
an exercise stress test, 24-h ECG recording and echocardio- 
gram are indicated, as well as possibly an electrophysiologic 
study to determine the site and duration of conduction delay. 
Recommendation. Athletes who are asymptomatic, with- 
out evidence of structural heart disease, in whom the first- 
degree AV block does not worsen with exercise, can partici- 
pate in all competitive sports. If underlying heart disease is
present, its n;fure and severity can independently dictate 
alternative r strictions. 
Type 2 Second-Degree ( Wnckebach) A V Block 
Wenckebach AV node block can be present in otherwise 
normal, well trained endurance athletes (7). Recommended 
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tests include a 1Ziead ECG, exercise t st and echocardiogram. 
A 24-h ECG recording during athletic activity may be indicated 
in some athletes. In those athletes with type 1 second-degree 
AV block and coexisting bundle branch block, eiectrophysi- 
ok@ study may be indicated to identify the presence of
His-Purkinje Wenckebach block 
1. Athletes with a structurai9y normal heart and no wors- 
ening or actual improvement of AV block with ei~drcise or 
recov@ry can participate in a99 competitive sports. 
2. Athic;, PI with a structurally abnormal heart in whom AV 
Mock disappears or does not worsen with exercise orrecovery 
can participate in all competitive sports, as determined bythe 
limitations of the cardiac abnormality. 
3. Athletes without symptoms in whom type 1 second- 
degree AV block initialty appears ar worsens with exercise or
during the recovery period should be evaluated further (e.g., 
for pcwsibie intra- or infra-His block) and may require pace- 
maker therapy. Such athletes can participate in low intensity 
comptitive sports (class IA). 
4. Athletes treated with pacemakers should not engage in
competitive sports with a danger of 9mdi9y collision because 
such trauma may damage the pacemaker system. 
Type 2 Second-&Fe (Mobitz) AV Block 
The evolution and treatment of this abnormality s consid- 
ered to be the same as in acquired complete heart block. It 
should be treated with permanent pacing before any athletic 
activity (see Congenital Complete Heart Block. recommenda- 
tions 2 and 3). 
ital Complete Heati Block 
The clinical approach to evaluating the severity of the 
cardiovascular abnormality includes an echocardiogram, 12.
lead ECG, 24-h ECG recording during exercise and exercise 
stress test (exercise t sting should be performed at the same 
exercise l vel as that during the sports activity). 
RecQmm0n&tilMs 
1. Athletes with a structurally normal heart and norriral 
cardiac fun&m, no history of syncope ornear syncop, a narrow 
QRS complex, ventrictdar rates at rest MO to SO beats/min 
&easing with exertion, oor only occasional premature v ntric- 
ular comp9exes andno ventricular tachycardia uring exertion can 
participate in ail competitive sports (32). 
2 Athletes with ventricular rhythmia, symptoms of fa- 
tigue, near syncope or syncope should have a pacemaker 
implanted before they participate in competitive sports. Ath- 
letes with pacemakers should not participate in competitive 
sports with a danger of bodily collision because such trauma 
may damage the pacemaker system. Before allowing athletes 
to engage in these activities, an exercise test should be 
performed atthe level of activity demanded by the particular 
sport o be certain that he paced heart rate increases appro- 
priately. 
3. Athletes with abnormal hemodynamic status, as in an 
intracardiac shunt, cannot participate in any competitive sports 
without a pacemaker. Restrictions are the same as those in 
recommendation 2. 
Acquired Complete Heart 
This condition should be treated with pacing before any 
athletic activity (see Congenital Complete Heart Block, rec- 
ommecldations 2 and 3). Atblet~s wit 
participate in competitive sports 
collision because such trauma may damage the pacemaker 
system. 
Complete Right Bundle ~~rlc~ 
Evaluation i cludes a 9Ziead ECG, 24-h ECG recording, 
exercise t st and echocardiogram. 
R~m~endatio~. Athletes without ventricular arrhyth- 
mias who do not develop AV block with exercise and who have 
no symptoms can participate in ail competitive sports. This also 
applies to athletes with associated left-axis deviation. 
Complete Lefr Bundle Branch Block 
The evaluation includes a 9Ziead ECG, 24-h ECC, exercise 
test and ~~b~~cardio~~arn. Because oftke rarity of acquired left 
bundle branch block in children and its association with 
syncope from presumed paroxysmal AV block, an invasive 
eiectrophysioiogic study should be considered in young pa- 
tients (33). 
Recommendations 
1. Older athletes with acquired left bundle branch block 
should follow the recommendations u der Complete Right 
Bundle Branch Block. 
2. Athletes with a normal HV interval nd a normal AV 
conduction response topacing can participate in all competi- 
tive sports. 
3. Athletes with abnormal AV conduction characterized by 
an HV interval >!&I ms or a His-Purkinje block should have 
pacemaker implantation. They should be restricted from com- 
petitive sports with a danger of bodily collision because such 
trauma may damage the pacemaker system. 
Congenital Long QT Interval Syndrome 
The diagnosis of the long QT-QTU syndrome may be 
complex in some patients (34,35). Although a corrected QT 
interval (Bazett) of 440 to 450 ms has been used as the upper 
limit of normal, the diagnosis oflong QT syndrome should be 
made using not only the QT interval but also a history of 
symptoms, family history and ECG changes, uch as T wave 
aitemans or abnormal configuration. 
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9. Athletes with t 
TU interval syndrome are at risk fo 
activity; such athletes should be restricted from all competitive 
sports. 
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